CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sailong Pharmaceutical Group Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sailong Pharmaceutical Group Co Ltd
West Side, 2F, Everbright International
Trade Center, No. 47, Jida Haibin South
Phone: +86 7563882955p:+86 7563882955 ZHUHAI, GNG  519015  China Ticker: 002898002898
Business Summary
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Company’s main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
7389 Business services, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President NanguiCai 62 4/3/2024 4/3/2024
Chief Financial Officer JingGao 48 4/3/2024 4/3/2024
Executive Vice President, Director DawenLiu 35 4/3/2024 3/14/2023
8 additional Officers and Directors records available in full report.

General Information
Number of Employees: 483 (As of 12/31/2023)
Outstanding Shares: 176,000,000 (As of 3/31/2024)
Shareholders: 19,654
Stock Exchange: SHE
Fax Number: +86 7563352738


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024